Novartis (Radioligand Therapy)

Overview

Novartis is a major manufacturer of approved radioligand therapies, built substantially on its acquisition of Advanced Accelerator Applications (AAA) and Endocyte. This is a neutral, factual profile focused on marketed radiopharmaceuticals relevant to clinical practice; it is not promotional and carries no endorsement.

Approved radiopharmaceuticals

Companion diagnostics

Associated PSMA and somatostatin-receptor PET imaging agents support patient selection for the therapies above (see the respective tracer pages).

Pipeline & context

The radioligand-therapy field is expanding toward next-generation targets and isotopes (including alpha emitters and new ligands). Specific pipeline programs and approval status change frequently; verify current details against primary regulatory and company sources at time of use.

Two established radioligand therapies

Novartis is a major radioligand-therapy manufacturer (built on its AAA and Endocyte acquisitions), with two established products in routine practice: Pluvicto (¹⁷⁷Lu-PSMA-617) for PSMA-positive mCRPC and Lutathera (¹⁷⁷Lu-DOTATATE) for SSTR-positive GEP-NET (adults and ≥12 y), each paired with a companion PET diagnostic (PSMA / somatostatin-receptor) for patient selection. This is a neutral factual profile, not an endorsement — pipeline and approval status change quickly, so treat forward-looking claims as time-sensitive.

High-Yield Pearls

• Pluvicto (¹⁷⁷Lu-PSMA-617) and Lutathera (¹⁷⁷Lu-DOTATATE) are the two established Novartis radioligand therapies in routine practice.
• Company/industry information changes quickly — treat pipeline claims as time-sensitive.